X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA ALKEM LABORATORIES ELDER PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x -0.2 - - View Chart
P/BV x 0.1 7.3 1.4% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ELDER PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
ALKEM LABORATORIES
Mar-16
ELDER PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3801,589 23.9%   
Low Rs1881,232 15.3%   
Sales per share (Unadj.) Rs491.2417.5 117.7%  
Earnings per share (Unadj.) Rs-3.256.3 -5.7%  
Cash flow per share (Unadj.) Rs14.464.7 22.3%  
Dividends per share (Unadj.) Rs012.70 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs376.5292.9 128.5%  
Shares outstanding (eoy) m20.54119.57 17.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.4 17.1%   
Avg P/E ratio x-89.325.1 -356.3%  
P/CF ratio (eoy) x19.721.8 90.4%  
Price / Book Value ratio x0.84.8 15.7%  
Dividend payout %022.6 0.0%   
Avg Mkt Cap Rs m5,833168,653 3.5%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1799,171 23.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m10,08949,915 20.2%  
Other income Rs m2571,645 15.6%   
Total revenues Rs m10,34651,561 20.1%   
Gross profit Rs m-7928,482 -9.3%  
Depreciation Rs m3611,006 35.9%   
Interest Rs m2,756671 411.0%   
Profit before tax Rs m-3,6538,451 -43.2%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1251,606 7.8%   
Profit after tax Rs m-656,731 -1.0%  
Gross profit margin %-7.817.0 -46.2%  
Effective tax rate %-3.419.0 -18.0%   
Net profit margin %-0.613.5 -4.8%  
BALANCE SHEET DATA
Current assets Rs m9,24027,062 34.1%   
Current liabilities Rs m9,99815,324 65.2%   
Net working cap to sales %-7.523.5 -31.9%  
Current ratio x0.91.8 52.3%  
Inventory Days Days4667 69.6%  
Debtors Days Days6041 145.2%  
Net fixed assets Rs m10,12412,610 80.3%   
Share capital Rs m206239 86.0%   
"Free" reserves Rs m5,58234,490 16.2%   
Net worth Rs m7,73435,027 22.1%   
Long term debt Rs m4,8891,212 403.5%   
Total assets Rs m22,88254,387 42.1%  
Interest coverage x-0.313.6 -2.4%   
Debt to equity ratio x0.60 1,827.6%  
Sales to assets ratio x0.40.9 48.0%   
Return on assets %11.813.6 86.4%  
Return on equity %-0.819.2 -4.4%  
Return on capital %22.324.9 89.8%  
Exports to sales %3.012.9 23.5%   
Imports to sales %0.43.1 13.8%   
Exports (fob) Rs m3076,461 4.7%   
Imports (cif) Rs m431,540 2.8%   
Fx inflow Rs m3076,563 4.7%   
Fx outflow Rs m1253,012 4.2%   
Net fx Rs m1813,552 5.1%   
CASH FLOW
From Operations Rs m11,7547,259 161.9%  
From Investments Rs m-5611,864 -30.1%  
From Financial Activity Rs m-6,762-9,273 72.9%  
Net Cashflow Rs m4,432-150 -2,954.5%  

Share Holding

Indian Promoters % 39.6 66.9 59.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 33.1 22.7%  
FIIs % 16.8 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 0.0 -  
Shareholders   16,479 68,381 24.1%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   IPCA LABS  NOVARTIS  PANACEA BIOTECH  MERCK LTD  SANOFI INDIA  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS